# HS-20093

Source: https://onco.cc/drugs/hs-20093/  
OnCo record `hs-20093` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HS-20093 is an experimental investigational agent whose form is not stated in the registry from Hansoh BioMedical R&D in phase 3 trials for osteosarcoma, non-small-cell lung cancer and sarcomas, with its target not yet stated publicly.

## Summary

HS-20093 is an investigational agent whose form is not stated in the registry developed by Hansoh BioMedical R&D and Jiangsu HengRui Medicine. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants in all subjucts will receive HS-20093 at 10mg/kg. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06935409 (Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure) and NCT06498479 (ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer), in osteosarcoma, non-small-cell lung cancer, sarcomas, prostate cancer and head and neck squamous cell carcinoma. The largest, NCT06498479, plans to enrol 460 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of HS-20093: https://clinicaltrials.gov/search?intr=HS-20093

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- trials: [A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07736612/), [A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S](https://onco.cc/trials/nct07464327/), [A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06526624/), [A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer](https://onco.cc/trials/nct07230106/), [ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas](https://onco.cc/trials/nct05830123/), [ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct06007729/), [ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06498479/), [HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors](https://onco.cc/trials/nct06112704/), [Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure](https://onco.cc/trials/nct06935409/)

---
JSON: https://onco.cc/api/v1/entities/hs-20093.json